{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:04Z","timestamp":1790697844577,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01220-z","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T11:05:23Z","timestamp":1649415923000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options"],"prefix":"10.1016","volume":"19","author":[{"given":"Rachel","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Glaubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-2371","authenticated-orcid":false,"given":"Jens","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01220-z_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.21068","article-title":"History of infection before the onset of juvenile dermatomyositis: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry","volume":"53","author":"Pachman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: Expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1007\/s13311-022-01220-z_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"The Lancet"},{"key":"10.1007\/s13311-022-01220-z_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0889-857X(02)00030-3","article-title":"Muscle biopsy findings in inflammatory myopathies","volume":"28","author":"Dalakas","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1007\/s13311-022-01220-z_bib9","unstructured":"Mavroudis I, Petridis F, Kazis D. Inclusion body myositis. Genetics, biomarkers and muscle biopsy. Int J Neurosci. 2020;1\u201310."},{"key":"10.1007\/s13311-022-01220-z_bib10","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib11","doi-asserted-by":"crossref","unstructured":"Miller FW, Chen W, O'Hanlon TP, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun. 2015;16:470\u201380.","DOI":"10.1038\/gene.2015.28"},{"key":"10.1007\/s13311-022-01220-z_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for myositis","volume":"4","author":"Barsotti","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/13543784.2021.2003776","article-title":"Inflammatory myopathies: Shedding light on promising agents and combination therapies in clinical trials","volume":"30","author":"Zeng","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1007\/s13311-022-01220-z_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X19886494","article-title":"New insights into the treatment of myositis","volume":"12","author":"Glaubitz","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1007\/s13311-022-01220-z_bib16","first-page":"1011","article-title":"Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity","volume":"35","author":"de Souza","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01220-z_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","article-title":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","volume":"46","author":"Hoa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib19","doi-asserted-by":"crossref","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (ProDERM Study). Medicine (Baltimore). 2021;100:e23677.","DOI":"10.1097\/MD.0000000000023677"},{"key":"10.1007\/s13311-022-01220-z_bib20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00296-019-04254-3","article-title":"Intravenous human immunoglobulin and\/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies","volume":"39","author":"de Souza","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1007\/s13311-022-01220-z_bib21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01220-z_bib22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/rheumatology\/keaa459","article-title":"Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study","volume":"60","author":"Lim","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: Proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01220-z_bib26","doi-asserted-by":"crossref","unstructured":"Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol (Hoboken, N.J.). 2021;73:858\u201365.","DOI":"10.1002\/art.41602"},{"key":"10.1007\/s13311-022-01220-z_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01220-z_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: Update on pathogenesis and treatment","volume":"15","author":"Naddaf","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-022-01220-z_bib30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01220-z_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01220-z_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01220-z_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/BOR.0000000000000436","article-title":"Inclusion body myositis: Advancements in diagnosis, pathomechanisms, and treatment","volume":"29","author":"Schmidt","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib34","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","article-title":"Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies","volume":"58","author":"de Souza","year":"2018","journal-title":"Adv Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib37","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: Differential effects in a real-life population","volume":"53","author":"Unger","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib38","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: Results from the AIR registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib39","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib42","doi-asserted-by":"crossref","unstructured":"Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol (Hoboken, N.J.). 2014;66:740\u20139.","DOI":"10.1002\/art.38270"},{"key":"10.1007\/s13311-022-01220-z_bib43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","article-title":"Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study","volume":"58","author":"Leclair","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/BOR.0b013e32833f1970","article-title":"Interstitial lung disease and idiopathic inflammatory myopathies: Progress and pitfalls","volume":"22","author":"Labirua","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib45","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib46","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib47","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib48","doi-asserted-by":"crossref","unstructured":"Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One. 2015;10:e0133702.","DOI":"10.1371\/journal.pone.0133702"},{"key":"10.1007\/s13311-022-01220-z_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): Study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"10.1007\/s13311-022-01220-z_bib50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/CND.0000000000000208","article-title":"Case of anti-single recognition particle-mediated necrotizing myopathy after influenza vaccination","volume":"19","author":"Mamarabadi","year":"2018","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1007\/s13311-022-01220-z_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","article-title":"Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature","volume":"15","author":"Binns","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1007\/s13311-022-01220-z_bib52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1007\/s13311-022-01220-z_bib53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/CND.0000000000000248","article-title":"Favorable response in statin-naive paraneoplastic anti-HMGCR antibody-associated myopathy to single dose of rituximab and persistent remission with management of underlying lung cancer","volume":"21","author":"Waheed","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1007\/s13311-022-01220-z_bib54","doi-asserted-by":"crossref","unstructured":"Zhang W, Prince HM, Reardon K. Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab. BMJ Case Rep. 2019;12:e232406.","DOI":"10.1136\/bcr-2019-232406"},{"key":"10.1007\/s13311-022-01220-z_bib55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib56","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/art.34465","article-title":"Interleukin-1 and tumor necrosis factor \u03b1 blockade treatment of experimental polymyositis in mice","volume":"64","author":"Sugihara","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib57","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2004.032359","article-title":"Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: In vitro regulation with specific cytokine inhibitors","volume":"64","author":"Chevrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01220-z_bib59","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib60","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/rheumatology\/keh539","article-title":"Advanced refractory polymyositis responding to infliximab","volume":"44","author":"Anandacoomarasamy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib61","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib62","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib63","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib64","doi-asserted-by":"crossref","unstructured":"Brunasso AMG, Aberer W, Massone C. New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review. Scientific World J. 2014;2014:179180.","DOI":"10.1155\/2014\/179180"},{"key":"10.1007\/s13311-022-01220-z_bib65","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","article-title":"Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A","volume":"60","author":"Okiyama","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","article-title":"IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis","volume":"176","author":"Scuderi","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01220-z_bib67","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib68","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","article-title":"The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome","volume":"55","author":"Murphy","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib69","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","article-title":"A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?","volume":"53","author":"Kondo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib70","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib71","doi-asserted-by":"crossref","unstructured":"Li S, Li W, Jiang W, et al. The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies: an open-label pilot study. Front Pharmacol. 2021;12:635654.","DOI":"10.3389\/fphar.2021.635654"},{"key":"10.1007\/s13311-022-01220-z_bib72","unstructured":"Aggarwal R, Rockette H, Venturupalli S, et al. Tocilizumab in myositis: results of a phase IIb double-blind randomized controlled trial. Arthritis Rheumatol. 2020:suppl 10."},{"key":"10.1007\/s13311-022-01220-z_bib73","doi-asserted-by":"crossref","unstructured":"Bolko L, Jiang W, Tawara N, et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021;31:e12955.","DOI":"10.1111\/bpa.12955"},{"key":"10.1007\/s13311-022-01220-z_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01220-z_bib75","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01220-z_bib76","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01220-z_bib77","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib78","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Krystufkov\u00e1","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib79","unstructured":"Chadha P, Narain S, Nandkumar P, et al. Safety and efficacy of belimumab in the treatment of adult idiopathic inflammatory myositis (polymyositis and dermatomyositis). Arthritis Rheumatol. 2021:(suppl 10)."},{"key":"10.1007\/s13311-022-01220-z_bib80","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00296-010-1692-y","article-title":"Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: Correlation to disease activity","volume":"32","author":"Mielnik","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1007\/s13311-022-01220-z_bib81","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib82","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01220-z_bib83","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3899\/jrheum.180060","article-title":"Complement C5-blocking agent in refractory dermatomyositis","volume":"45","author":"Faguer","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-022-01220-z_bib84","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01220-z_bib85","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib86","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","article-title":"Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level","volume":"103","author":"Lutz","year":"2004","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01220-z_bib87","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-022-01220-z_bib88","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-022-01220-z_bib89","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: Molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1007\/s13311-022-01220-z_bib90","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-022-01220-z_bib91","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01220-z_bib92","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis: Long-term extension of RESILIENT","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01220-z_bib93","doi-asserted-by":"crossref","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","article-title":"Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis","volume":"95","author":"Sivakumar","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01220-z_bib94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14712598.2018.1425388","article-title":"Alemtuzumab for the treatment of multiple sclerosis","volume":"18","author":"Evan","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1007\/s13311-022-01220-z_bib95","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01220-z_bib96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12883-016-0568-5","article-title":"Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM","volume":"16","author":"Schmidt","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-022-01220-z_bib97","first-page":"1368","article-title":"Inclusion body myositis treated with alemtuzumab","volume":"6","author":"S\u00e1","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1007\/s13311-022-01220-z_bib98","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/rheumatology\/keu484","article-title":"Long-term efficacy of alemtuzumab in polymyositis","volume":"54","author":"Ruck","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-022-01220-z_bib99","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/aws046","article-title":"Nitric oxide stress in sporadic inclusion body myositis muscle fibres: Inhibition of inducible nitric oxide synthase prevents interleukin-1\u03b2-induced accumulation of \u03b2-amyloid and cell death","volume":"135","author":"Schmidt","year":"2012","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01220-z_bib100","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/brain\/awn053","article-title":"Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle","volume":"131","author":"Schmidt","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01220-z_bib101","doi-asserted-by":"crossref","unstructured":"Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1\u03b2 receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm. 2019;6:e581.","DOI":"10.1212\/NXI.0000000000000581"},{"key":"10.1007\/s13311-022-01220-z_bib102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01220-z_bib103","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01220-z_bib104","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01220-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:44Z","timestamp":1761807704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011121"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01220-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01220-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}